Özet:

CHEMERIN is a signal molecule and a new chemotactic protein with various autokrin and parakrin effects, which recently joined the adipokin family. In recent years, chemerin and its receptor have been found to be expressed in the liver, kidney, pancreas, hypofysis, plasenta, ovarian and testicles, with high levels in adiposites. It is known that through this organ and tissue energy affects homeostasis, glucose metabolism, inflammation and many physiological processes. There are increasing evidence of this adipogenesis, which has been shown to play a role in metabolism, energy metabolism and inflammation, about the metabolic syndrome (MetS), obesity, type 2 diabetes mellitus (T2DM), cardiovascular diseases, Crohn's disease, arthritis and the role in cancer. In particular, chemerine has been suggested as the hypothesis of a possible link between obesity and the development of T2DM. It has also been found that plasma chemerin levels have a positive correlation with body mass index, hunger serum insulin, hunger blood glucose, plasma triglycerides and total serum cholesterol and have a negative correlation with high-intensity lipoprotein (HDL). In general, these findings suggest that the levels of chemerin in circulation are linked to fertilization and metabolic syndrome, and that visual adiposis is a variable source of chemerin in obese individuals. Chemerin; reducing the level of insulin, increasing the use of glucose, influencing the methS indicators by inhibiting glucose homeostasis; T2DM by inhibiting glucogen synthesis; inflammation by regulating adiposite differentiation and chemotaxis; GLUT-4, regulating fat acid synthesis, adiponectin and leptin release. Therefore, it is important to determine and control the levels of chemerine adipokinine in circulation, which is associated with obesity, T2DM, cardiovascular diseases, inflammation, metabolic syndrome and many more diseases. In the literature scan, it is often observed that people with obesity and metabolic syndrome have high levels of chemerin in circulation. This collection includes less-treated inflammation, polycystic over syndrome and other metabolic effects, along with the effects of chemerin on obesity and metabolic syndrome.

Anahtar Kelimeler:

Özet:

OBJECTIVE: Chemerin secreted from adipose tissue is a signal molecule with a variety of autocrine and paracrine effects and a new chemotactic protein that recently joined the adipokine family. In recent years, chemerin and its receptor are expressed at the highest levels in adipocytes and less expressed than in the liver, kidney, pancreas, pituitary, placenta, ovary and testes. Through these organs and tissues it is known that it affects energy homeostasis, glucose metabolism, inflammation and many physiological processes. There is growing evidence that this adipokine has been shown to play a role in adipogenesis, energy metabolism and inflammation, its role in metabolic syndrome (MetS), obesity, Type 2 Diabetes Mellitus (T2DM), cardiovascular diseases, Crohn’s disease, arthritis and cancer. In particular, chemerin has been suggested as a hypothesis of a possible link between obesity and the development of T2DM. It was also found that plasma chemerin levels correlated positively with body mass index, fasting serum insulin, fasting blood glucose, plasma triglycerides and total serum cholesterol and negatively correlated with high density lipoprotein (HDL). In general, these findings indicate that circulating levels of chemerin are dependent on adiposity and metabolic syndrome, suggesting that visceral adipose is a replaceable source of chemerin in obese individuals. Chemerin affects glucose homeostasis by decreasing insulin levels and increasing glucose uptake; T2DM by inhibiting glycogen synthase; inflammation by regulating adipocyte differentiation and chemotaxis; MetS markers by regulating the release of GLUT-4, fatty acid synthase, adiponectin and leptin. Therefore, it is important to determine the levels of circulating levels of chemerin adipokinin in relation to obesity, T2DM, cardiovascular diseases, inflammation, metabolic syndrome and many other diseases. In the literature, it is frequently observed that circulating chemerin levels are high in individuals with obese and metabolic syndrome. In this review, chemerinin is associated with the effects of obesity and the metabolic syndrome, as well as less-studied inflammation, polycystic ovarian syndrome and other metabolic effects.